4/23/2024 | SP | New Issue: Citi sells $4.52 million autocallable variable coupon market-linked notes on four stocks
|
4/5/2024 | SP | New Issue: HSBC prices $3.39 million contingent income barrier autocalls with memory on Amgen
|
3/8/2024 | SP | New Issue: Citigroup prices $3.07 million contingent income autocallables linked to Amgen
|
1/28/2024 | SP | New Issue: Citi sells $1.17 million autocallable variable coupon market-linked notes on four stocks
|
1/5/2024 | SP | New Issue: Citigroup prices $1.03 million autocallable securities linked to basket of 10 stocks
|
12/1/2023 | SP | New Issue: UBS prices $154,000 buffered return optimization securities on Amgen
|
11/15/2023 | SP | New Issue: UBS prices $3.09 million contingent income autocallable securities on Amgen
|
10/11/2023 | BKGNIG | Fitch trims Amgen
|
10/6/2023 | HYLM | Horizon repays, redeems over $2.6 billion in debt in Amgen acquisition
|
10/6/2023 | BK | Horizon repays, redeems over $2.6 billion in debt in Amgen acquisition
|
9/5/2023 | IG | Amgen acquisition of Horizon Therapeutics clears FTC
|
6/29/2023 | SP | New Issue: UBS prices $1 million trigger yield notes linked to Amgen, Russell index
|
6/5/2023 | SP | New Issue: Barclays prices $241,000 autocallable contingent coupon barrier notes on stock basket
|
5/31/2023 | SP | New Issue: Issuer prices $280,500 contingent income autocallables linked to Amgen
|
3/9/2023 | BK | Amgen enters $4 billion restated revolver, terminates bridge loan
|
2/17/2023 | IG | Market Commentary: High-grade bond issuance jumps; Amgen among record deals; busy week ahead anticipated
|
2/16/2023 | IG | New Issue: Amgen sells $24 billion senior note offering in eight parts
|
2/15/2023 | BKGNHYIG | Moody’s assigns Amgen notes Baa1
|
2/14/2023 | BKGNHYIG | S&P assigns Amgen notes BBB+
|
2/14/2023 | BKGNHYIG | Fitch rates Amgen loans, notes BBB+
|
2/14/2023 | IG | Amgen to sell fixed-rate notes in eight parts via four bookrunners
|
2/13/2023 | BKGNHYIG | Moody’s turns Amgen outlook to negative
|
2/1/2023 | SP | New Issue: Barclays prices $2.25 million autocallable contingent coupon barrier notes on 10-stock basket
|
12/22/2022 | BK | Amgen enters $4 billion term loan credit agreement with two tranches
|
12/13/2022 | BKGNHYIG | S&P puts Horizon on positive watch
|
12/13/2022 | BKGNHYIG | Moody's eyes Horizon for upgrade
|
12/12/2022 | BKGNHYIG | Moody's eyes Amgen downgrade
|
12/12/2022 | BKGNHYIG | S&P snips Amgen
|
12/12/2022 | BKIG | Amgen gets $28.5 billion bridge loan commitment for Horizon purchase
|
12/12/2022 | BKGNHYIG | Fitch places Amgen on watch
|
11/3/2022 | SP | New Issue: UBS prices $2.36 million contingent income autocallable securities on Amgen
|
11/1/2022 | SP | New Issue: JPMorgan prices $241,000 autocallable contingent interest notes on pharma stocks
|
8/25/2022 | SP | New Issue: UBS prices $1.31 million trigger autocallable contingent yield notes on Amgen
|
8/15/2022 | IG | New Issue: Amgen prices $3 billion of senior notes due 2029, 2033, 2053
|
8/15/2022 | BKGNIG | S&P gives Amgen notes A-
|
8/15/2022 | BKGNIG | Fitch rates Amgen notes BBB+
|
8/15/2022 | BKGNIG | Moody's gives Baa1 to Amgen notes
|
8/15/2022 | IG | Amgen to sell fixed-rate notes in three parts via four bookrunners
|
8/8/2022 | BKGNIG | S&P turns Amgen view to negative
|
7/8/2022 | SP | New Issue: Morgan Stanley prices $1.41 million worst-of fixed coupon autocallable RevCons on stocks
|
4/26/2022 | SP | New Issue: Credit Suisse sells $1.75 million accelerated barrier notes on basket
|
3/30/2022 | SP | New Issue: JPMorgan prices $905,000 contingent interest autocalls on two stocks
|
3/1/2022 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Amgen
|
2/18/2022 | IG | Market Commentary: Investment-grade issuers Amgen, Verizon, DTE, Mizuho price green bonds; paper mostly improves
|
2/17/2022 | GN | New Issue: Amgen sells $750 million 3% senior green notes due 2029
|
2/17/2022 | IG | New Issue: Amgen sells $4 billion of notes in four parts
|
2/17/2022 | BKGNIG | Fitch gives Amgen notes BBB+
|
2/17/2022 | BKGNIG | S&P rates Amgen notes A-
|
2/17/2022 | BKGNIG | Moody's assigns Amgen notes Baa1
|
2/17/2022 | GNIG | Amgen to sell fixed-rate notes, including green notes, in four parts
|
2/16/2022 | SP | New Issue: BMO sells $2.59 million enhanced return notes on stock basket
|
2/16/2022 | SP | New Issue: BMO sells $2.6 million buffer enhanced return notes on stock basket
|
2/9/2022 | SP | New Issue: JPMorgan prices $1.84 million contingent income autocallables on Amgen
|
12/20/2021 | SP | New Issue: UBS prices $350,000 trigger phoenix autocallables linked to Amgen
|
12/7/2021 | SP | New Issue: HSBC sells $710,000 contingent income barrier autocalls on Gilead, Amgen, Merck
|
10/31/2021 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Amgen
|
10/1/2021 | SP | New Issue: RBC sells $3.4 million trigger autocallable contingent yield notes on Amgen
|
8/21/2021 | SP | New Issue: Credit Suisse sells $8.78 million autocallable contingent income securities on pharma stocks
|
8/6/2021 | IG | New Issue: Amgen sells $5 billion notes in four parts due 2028, 2032, 2041, 2052
|
8/5/2021 | BKIG | Fitch gives Amgen notes BBB+
|
8/5/2021 | IG | Amgen to offer senior notes in tranches due 2028, 2032, 2041, 2052; talk emerges
|
8/5/2021 | BKIG | Moody's rates Amgen notes Baa1
|
8/5/2021 | BKIG | S&P assigns Amgen notes A-
|
8/5/2021 | IG | Amgen to offer senior notes in tranches due 2028, 2032, 2041, 2052
|
4/7/2021 | SP | New Issue: Credit Suisse sells $1.52 million contingent coupon autocallable yield notes on stocks
|
4/7/2021 | SP | New Issue: Credit Suisse sells $2.71 million contingent coupon autocallable yield notes on stocks
|
3/15/2021 | SP | New Issue: UBS prices $5 million trigger autocallable contingent yield notes on stock basket
|
3/11/2021 | SP | New Issue: UBS prices $15.4 million trigger autocallable contingent yield notes on stock basket
|
3/1/2021 | SP | New Issue: Credit Suisse sells $1.41 million ARES on basket of 10 stocks
|
3/1/2021 | SP | New Issue: Credit Suisse sells $2.99 million ARES on basket of 10 stocks
|
2/25/2021 | SP | New Issue: UBS sells $15.4 million contingent yield trigger autocallables on stock basket
|
2/10/2021 | SP | New Issue: Citi prices $1.36 million contingent coupon autocalls on three stocks
|
12/29/2020 | SP | New Issue: GS Finance sells $1.71 million leveraged basket-linked notes on 23 stocks
|
12/27/2020 | SP | New Issue: UBS sells $5 million trigger autocallable contingent yield notes on basket of stocks
|
12/24/2020 | SP | New Issue: UBS prices $110,000 trigger phoenix autocallables linked to Amgen
|
11/22/2020 | SP | New Issue: UBS sells $6.65 million trigger autocallable contingent yield notes on basket of stocks
|
11/6/2020 | SP | New Issue: UBS prices $8.48 million contingent income autocalls on Amgen
|
10/26/2020 | SP | New Issue: GS Finance sells $1.21 million callable contingent coupon equity notes on Amgen
|
9/29/2020 | SP | New Issue: UBS prices $9.08 million contingent income autocalls on Amgen
|
9/6/2020 | SP | New Issue: UBS sells $3.25 million trigger autocallable contingent yield notes on Amgen
|
8/26/2020 | SP | UBS to price trigger autocallable contingent yield notes on Amgen
|
8/14/2020 | IGLM | Amgen sets pricing terms for nine exchange offers, increases cap
|
8/13/2020 | IGLM | Amgen gives early results of exchange offers for cash and new notes
|
7/30/2020 | BKIG | Moody’s rates Amgen notes Baa1
|
7/30/2020 | BKIG | S&P assigns Amgen notes A-
|
7/30/2020 | IGLM | Amgen begins nine exchange offers for cash and new notes due 2053
|
6/26/2020 | SP | New Issue: Barclays sells $345,000 phoenix autocallable notes on three stocks
|
6/26/2020 | SP | New Issue: Barclays sells $1.5 million phoenix autocallable notes on three stocks
|
6/18/2020 | SP | New Issue: Goldman prices $7.88 million leveraged basket-linked notes on 62 stocks
|
5/8/2020 | SP | New Issue: GS Finance prices $4.05 million capped trigger securities on basket of 20 stocks
|
5/6/2020 | BKIG | Fitch rates Amgen notes BBB+
|
5/5/2020 | IG | New Issue: Amgen prices $4 billion four-tranche offering of senior notes
|
5/4/2020 | EMHYPFPV | Market Commentary: High-grade supply heavy; Apple, Starbucks, Amgen, Marsh in primary
|
5/4/2020 | IG | Market Commentary: High-grade supply heavy; Apple, Starbucks, Amgen, Marsh in primary; spreads mostly flat
|
5/4/2020 | IG | Moody's downgrades ADO
|
5/4/2020 | IG | Moody's downgrades ADO
|
5/4/2020 | BKIG | Moody's assigns Amgen notes Baa1
|
5/4/2020 | BKIG | S&P rates Amgen notes A-
|
5/4/2020 | IG | Market Commentary: Morning Commentary: High-grade supply heavy; Apple, Starbucks, Altria, Amgen on deck
|
5/4/2020 | IG | Amgen to price tap of 2027, 2040, 2050 notes, new notes due 2031
|
3/4/2020 | SP | New Issue: Citigroup prices $689,000 contingent coupon autocallables on AbbVie, Amgen
|
2/21/2020 | EMHYPFPV | Market Commentary: W.W. Grainger prices; strong volume forecast; Citrix, Otis notes firm; Omnicom, Amgen ease
|
2/21/2020 | IG | Market Commentary: W.W. Grainger prices; strong volume forecast; Citrix, Otis notes firm; Omnicom, Amgen ease
|
2/21/2020 | SP | New Issue: Morgan Stanley sells $3.3 million contingent income autocalls on three stocks
|
2/19/2020 | IG | Market Commentary: Otis, BP, Tennessee Gas, Halliburton, KLA, Omnicom, UDR tap primary; SSA supply ahead
|
2/19/2020 | IG | Market Commentary: Morning Commentary: Otis, Omnicom, Halliburton, BP, Tennessee Gas, KLA, UDR on tap
|
2/18/2020 | EMHYPFPV | Market Commentary: Amgen, MUFG, Mizuho, FirstEnergy, BNP, Republic Services flood primary
|
2/18/2020 | IG | Market Commentary: Amgen, MUFG, Mizuho, FirstEnergy, BNP, Republic Services flood primary; Otis eyed
|
2/18/2020 | IG | New Issue: Amgen prices $5 billion five-tranche offering of senior notes
|
2/18/2020 | IG | Market Commentary: Morning Commentary: Amgen, Mizuho, MUFG, Brookfield, FirstEnergy on tap; Otis eyed
|
2/18/2020 | IGLM | Amgen to redeem all 3.45%, 4.1%, 1.85% notes, some 3.875% notes
|
2/18/2020 | IG | Amgen offers fixed-rate notes in five parts to fund notes redemption
|
2/17/2020 | SP | New Issue: JPMorgan sells $429,000 autocallable contingent interest notes on stocks
|
2/11/2020 | SP | Morgan Stanley plans contingent income autocallables on three stocks
|
2/11/2020 | SP | New Issue: RBC prices $645,000 contingent coupon barrier autocalls on three stocks
|
1/27/2020 | SP | New Issue: Citigroup prices $2.03 million contingent coupon autocallables on three stocks
|
1/16/2020 | SP | New Issue: Scotia sells $6.05 million capped enhanced participation notes on basket of 49 stocks
|
1/3/2020 | SP | New Issue: Barclays prices $3.66 million contingent income autocallables on Amgen
|
12/30/2019 | SP | New Issue: Credit Suisse $2.25 million contingent coupon autocallable yield notes on three stocks
|
12/26/2019 | SP | New Issue: Morgan Stanley prices $1.45 million contingent income autocallables on three stocks
|
12/26/2019 | SP | New Issue: Morgan Stanley prices $1.98 million contingent income autocallables on three stocks
|
12/23/2019 | SP | Barclays plans contingent income autocallables linked to Amgen
|
12/16/2019 | SP | Credit Suisse plans contingent coupon autocallable yield notes on stocks
|
12/16/2019 | SP | Morgan Stanley plans contingent income autocallables tied to stocks
|
12/16/2019 | SP | Morgan Stanley plans contingent income autocallables linked to stocks
|
12/12/2019 | BK | Amgen gets $2.5 billion five-year restated revolving credit facility
|
12/9/2019 | SP | New Issue: JPMorgan prices $1.2 million contingent interest autocalls on two stocks
|
11/21/2019 | BKIG | S&P trims Amgen
|
11/21/2019 | SP | New Issue: Credit Suisse sells $2 million contingent coupon autocallable yield notes on pharma
|
11/15/2019 | SP | New Issue: HSBC prices $298,000 contingent income autocallables linked to Amgen
|
11/4/2019 | BKIG | Fitch ups Amgen
|
9/10/2019 | SP | New Issue: HSBC prices $1.26 million contingent income autocallables on Amgen
|
9/5/2019 | SP | New Issue: Citigroup prices $2.21 million contingent income autocallables linked to Amgen
|
9/5/2019 | SP | HSBC plans contingent income autocallables linked to Amgen
|
8/26/2019 | BKIG | S&P puts Amgen on negative watch
|
8/21/2019 | SP | New Issue: JPMorgan sells $332,000 contingent interest autocalls tied to Disney, Sony, Amgen
|
8/5/2019 | SP | New Issue: Morgan Stanley prices $4.61 million contingent income autocallables on Amgen
|
7/25/2019 | SP | Morgan Stanley plans contingent income autocallables tied to Amgen
|
6/25/2019 | SP | UBS plans trigger autocallable contingent yield notes linked to Amgen
|
4/23/2019 | SP | New Issue: UBS prices $584,000 trigger phoenix autocallables linked to Amgen
|
3/13/2019 | SP | New Issue: UBS sells $3.7 million trigger autocallable contingent yield notes on Amgen
|
2/25/2019 | SP | New Issue: BofA prices $8.94 million 8% STEP Income Securities tied to Amgen
|
2/13/2019 | SP | BofA to price 8% STEP Income Securities due 2020 linked to Amgen
|
1/4/2019 | BKIG | Fitch affirms Amgen
|
9/24/2018 | SP | New Issue: RBC prices $284,000 10.1% contingent coupon autocalls on three stocks
|
9/20/2018 | SP | New Issue: Morgan Stanley sells $2.17 million contingent income autocalls on Amgen
|
8/30/2018 | SP | New Issue: Barclays sells $5.42 million 8.25% contingent income autocalls on Amgen
|
8/27/2018 | SP | New Issue: Citi prices $3.95 million 8% contingent income autocalls tied to Amgen
|
8/17/2018 | SP | Barclays to sell contingent income autocallables tied to Amgen shares
|
8/16/2018 | SP | New Issue: RBC prices $542,000 8.85% contingent coupon autocalls on three stocks
|
8/15/2018 | SP | Citi plans 8% contingent income autocalls due 2021 tied to Amgen
|
5/16/2018 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Amgen
|
2/6/2018 | SP | New Issue: Barclays prices $3.35 million 9% contingent income autocallables tied to Amgen
|
2/2/2018 | BKIG | Moody’s affirms Amgen
|
2/1/2018 | SP | Barclays plans 8.6% contingent income autocallables tied to Amgen
|
2/1/2018 | SP | New Issue: Credit Suisse sells $2.22 million contingent coupon autocallable yield notes on stocks
|
1/30/2018 | SP | New Issue: RBC prices $166,000 8.7% contingent coupon autocalls tied to two stocks
|
1/22/2018 | SP | Credit Suisse plans 10% contingent coupon autocallables on stocks
|
1/5/2018 | SP | RBC plans autocallable contingent coupon barrier notes tied to stocks
|
1/4/2018 | SP | New Issue: RBC sells $732,000 contingent coupon barrier autocalls on Amgen, Biogen
|
1/4/2018 | SP | New Issue: UBS sells $639,000 trigger autocallable contingent yield notes on two stocks
|
12/18/2017 | SP | UBS plans 8.25%-9.25% contingent yield trigger autocalls on stocks
|
11/21/2017 | SP | New Issue: RBC sells $2.83 million contingent coupon barrier autocalls on Amgen, Celgene
|
11/15/2017 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Amgen
|
11/8/2017 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Amgen
|
10/31/2017 | EMHYPFPV | Market Commentary: Lloyds sells $4 billion notes; Celgene, GATX, Philip Morris, Constellation, Amgen price
|
10/31/2017 | IG | Market Commentary: Lloyds sells $4 billion notes; Celgene, GATX, Philip Morris, Constellation, Amgen price
|
10/31/2017 | BKIG | S&P gives Amgen notes A
|
10/31/2017 | IG | New Issue: Amgen sells $1 billion of 3.2% 10-year senior notes at 87.5 bps spread
|
10/31/2017 | BKIG | Moody’s applies Baa1 to Amgen notes
|
10/31/2017 | IG | Market Commentary: Morning Commentary: Lloyds, Celgene, GATX, Philip Morris, Constellation, Amgen bonds on tap
|
10/31/2017 | IG | Amgen intends to sell 10-year fixed-rate notes via three bookrunners
|
10/30/2017 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Amgen
|
10/27/2017 | SP | New Issue: Morgan Stanley sells $1.14 million 8.28% contingent income autocalls tied to stocks
|
10/13/2017 | SP | RBC plans autocallable contingent coupon barrier notes on two stocks
|
9/27/2017 | SP | New Issue: RBC sells $150,000 contingent coupon barrier autocallables tied to Amgen, Bristol-Myers
|
9/15/2017 | SP | RBC plans two-year contingent coupon barrier autocallables on stocks
|
9/14/2017 | SP | New Issue: RBC sells $153,000 contingent coupon barrier autocallables on Amgen, Bristol-Myers
|
9/1/2017 | SP | RBC eyes autocallable contingent coupon barrier notes tied to stocks
|
8/31/2017 | SP | New Issue: Barclays prices $2.16 million phoenix autocallables tied to three stocks
|
8/29/2017 | SP | New Issue: RBC prices $260,000 contingent coupon barrier autocallables tied to two stocks
|
8/18/2017 | SP | RBC plans contingent coupon barrier autocallables tied to two stocks
|
8/17/2017 | SP | New Issue: RBC sells $1.04 million contingent coupon barrier autocallables tied to two stocks
|
8/16/2017 | SP | New Issue: HSBC sells $3.32 million contingent income step-up autocalls tied to Amgen
|
8/11/2017 | SP | Market Commentary: HSBC’s contingent income autocall tied to Amgen include step ups for more coupon payments
|
8/9/2017 | SP | HSBC plans three-year contingent income autocallables tied to Amgen
|
8/7/2017 | SP | RBC eyes autocallable contingent coupon barrier notes tied to stocks
|
7/27/2017 | SP | New Issue: RBC prices $693,000 contingent coupon barrier autocallables on Amgen, Bristol-Myers
|
7/14/2017 | SP | RBC plans contingent coupon autocallables on Amgen, Bristol-Myers
|
7/13/2017 | SP | New Issue: Barclays prices $5.44 million contingent income autocallables on Amgen
|
7/13/2017 | SP | New Issue: Credit Suisse sells $168,000 contingent coupon autocallable reverse convertibles on Amgen
|
7/6/2017 | SP | Barclays plans contingent income notes with step-up call level on Amgen
|
7/3/2017 | SP | New Issue: RBC sells $760,000 contingent coupon autocallables on Amgen, Medtronic
|
6/26/2017 | SP | New Issue: RBC prices $455,000 contingent coupon autocallables linked to Amgen, Bristol-Myers
|
6/21/2017 | SP | New Issue: HSBC prices $2.25 million 10% yield autocallables tied to three stocks
|
6/15/2017 | SP | RBC will price autocallable contingent coupon barrier notes on stocks
|
6/13/2017 | SP | New Issue: Credit Suisse sells $920,000 contingent coupon autocallable reverse convertibles on Amgen
|
6/8/2017 | SP | New Issue: HSBC prices $2.25 million autocallable yield notes tied to three stocks
|
6/2/2017 | SP | RBC plans contingent coupon barrier autocallables on Amgen, Medtronic
|
5/25/2017 | SP | New Issue: Credit Suisse sells $429,000 autocallable reverse convertibles on Amgen
|
5/10/2017 | SP | Credit Suisse plans 6.25% contingent coupon autocallable reverse convertibles tied to Amgen
|
5/9/2017 | BKIG | Fitch applies BBB to Amgen notes
|
5/9/2017 | IG | New Issue: Amgen gives details on $3.5 billion five-part issue of senior notes
|
5/8/2017 | EMHYPFPV | Market Commentary: Intel, Amgen price; Caterpillar sells add-on in reverse inquiry; utilities bring bonds
|
5/8/2017 | IG | Market Commentary: Intel, Amgen price notes; Caterpillar sells add-on in reverse inquiry; utilities bring bonds
|
5/8/2017 | IG | New Issue: Amgen prices $3.5 billion of senior notes in five tranches
|
5/8/2017 | BKIG | S&P rates Amgen notes A
|
5/8/2017 | BKIG | Moody’s applies Baa1 to Amgen notes
|
5/8/2017 | IG | Market Commentary: Morning Commentary: Intel, Caterpillar, Amgen in deal pipeline; Amgen notes modestly better
|
5/8/2017 | IG | Amgen intends to sell fixed- and floating-rate notes in five parts
|
5/5/2017 | SP | New Issue: Barclays sells $1.9 million phoenix autocallable notes on two stocks
|
3/30/2017 | SP | New Issue: RBC prices $1.61 million contingent coupon barrier autocallables tied to three stocks
|
3/29/2017 | SP | New Issue: Morgan Stanley prices $6.96 million contingent income autocallables linked to Amgen
|
3/24/2017 | SP | RBC eyes contingent coupon barrier autocallables tied to three stocks
|
3/17/2017 | SP | Morgan Stanley plans contingent income autocallables on Amgen
|
3/13/2017 | SP | New Issue: RBC prices $3 million of autocallable reverse convertibles on two stocks
|
3/13/2017 | SP | New Issue: RBC prices $62,000 of contingent coupon barrier autocallables on Amgen
|
3/1/2017 | SP | RBC plans contingent coupon barrier autocallables linked to Amgen
|
2/28/2017 | SP | New Issue: Credit Suisse prices $11.95 million Accelerated Return Notes on biotech stocks
|
2/14/2017 | SP | Credit Suisse plans Accelerated Return Notes on three biotech stocks
|
2/13/2017 | SP | New Issue: HSBC prices $1 million autocallables linked to biotechnology basket
|
2/9/2017 | SP | New Issue: HSBC prices $1 million autocallable notes linked to basket of biotech ETF, stocks
|
2/7/2017 | SP | New Issue: Morgan Stanley prices $6 million contingent income autocallables on three stocks
|
2/7/2017 | SP | HSBC plans autocallable notes linked to basket of biotech ETF, stocks
|
2/6/2017 | SP | New Issue: Citi prices $1.2 million contingent coupon autocallables tied to Amgen
|
1/30/2017 | SP | New Issue: RBC sells $3.12 million contingent coupon barrier autocallables tied to Amgen, Biogen
|
1/27/2017 | SP | New Issue: JPMorgan prices $1 million contingent interest autocallables tied to pharma stocks
|
1/26/2017 | SP | Citigroup plans contingent coupon autocallables linked to Amgen
|
1/23/2017 | SP | RBC plans contingent coupon barrier autocallables tied to two stocks
|
1/12/2017 | SP | JPMorgan plans contingent interest autocallables tied to three stocks
|
1/9/2017 | SP | Morgan Stanley plans contingent income notes linked to three stocks
|
12/23/2016 | SP | New Issue: HSBC prices $1 million 9% yield notes on Amgen, Biogen, Thermo Fisher shares
|
12/16/2016 | SP | HSBC set to price yield notes on Amgen, Biogen, Thermo Fisher shares
|
12/16/2016 | SP | New Issue: Credit Suisse sells $1.23 million 7.5% autocallable reverse convertibles on Amgen
|
12/6/2016 | SP | Credit Suisse plans 7.5%-9.5% autocall reverse convertibles on Amgen
|
11/29/2016 | SP | New Issue: Credit Suisse sells $3.53 million 8% autocallable reverse convertibles on Amgen
|
11/9/2016 | SP | Credit Suisse plans autocallable reverse convertibles on Amgen stock
|
11/1/2016 | SP | New Issue: Barclays sells $3.04 million phoenix autocallables tied to three stocks
|
10/13/2016 | SP | Barclays plans seven-year phoenix autocallables tied to Russell, S&P
|
9/20/2016 | SP | New Issue: JPMorgan prices $6.13 million contingent income autocallables linked to Amgen
|
9/13/2016 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Amgen
|
9/12/2016 | SP | JPMorgan plans contingent income autocallables linked to Amgen
|
9/9/2016 | SP | New Issue: JPMorgan prices $3.57 million contingent income autocallables on Amgen
|
8/26/2016 | SP | JPMorgan plans three-year contingent income autocallables on Amgen
|
8/25/2016 | EMHYPFPV | Market Commentary: NextEra prices $500 million; primary thins; Old Republic tightens; credit spreads flat
|
8/25/2016 | IG | Market Commentary: NextEra prices $500 million; primary thins; Old Republic tightens; credit spreads flat
|
8/25/2016 | IG | Market Commentary: Morning Commentary: NextEra remarkets; Old Republic firms; Amgen eases; credit spreads flat
|
8/24/2016 | EMHYPFPV | Market Commentary: Svensk, Symphony bring bonds; FHLBank to price; spreads ease; Visa, Westpac Banking firm
|
8/24/2016 | IG | Market Commentary: Swedish Export Credit, Symphony bring bonds; credit spreads ease; Visa, Westpac Banking firm
|
8/24/2016 | IG | Market Commentary: Morning Commentary: Primary action set; Westpac Banking, Amgen firm; Libor yield rises
|
8/12/2016 | IG | Market Commentary: Morning Commentary: Amgen, Bunge notes tighten in secondary market; credit spreads leak wider
|
8/11/2016 | BKCVIG | Fitch rates Amgen notes BBB
|
8/11/2016 | IG | New Issue: Amgen details pricing of $3.75 billion senior notes in four tranches
|
8/10/2016 | EMHYMUPFPV | Market Commentary: Amgen, FMS, Baxter among high-grade issuers; credit spreads soften; Duke Energy bonds improve
|
8/10/2016 | IG | Market Commentary: Amgen, FMS, Baxter among high-grade issuers; credit spreads soften; Duke Energy bonds improve
|
8/10/2016 | IG | New Issue: Amgen prices $3.75 billion of senior notes in four tranches
|
8/10/2016 | BK | Amgen to repay term loan credit agreement debt via new note offerings
|
8/10/2016 | BKIG | Moody’s assigns Baa1 to Amgen notes
|
8/10/2016 | BKIG | S&P rates Amgen notes A
|
8/10/2016 | IG | Amgen intends to price five-, seven- and 10-year senior notes and 4.4% notes due 2045
|
8/2/2016 | SP | New Issue: Barclays prices $7.89 million contingent income autocallables on Amgen
|
7/21/2016 | SP | Barclays plans contingent income autocallable securities on Amgen
|
7/7/2016 | SP | New Issue: Deutsche Bank prices $1.08 million autocallable securities on Amgen
|
6/10/2016 | IGLM | Amgen to issue $1.42 billion of 4.563% notes, $3.54 billion of 4.663% notes in exchange
|
5/25/2016 | IGLM | Amgen prices exchange offers for seven series of notes
|
5/13/2016 | BKIG | Fitch assigns BBB to Amgen notes
|
5/13/2016 | BKIG | Moody’s rates Amgen notes Baa1
|
5/13/2016 | IGLM | Amgen to issue new notes due 2048, 2051 in exchange for seven series
|
5/13/2016 | BKIG | S&P rates Amgen notes A
|
4/27/2016 | SP | New Issue: UBS prices $4.54 million of contingent income autocallables on Amgen
|
4/15/2016 | SP | UBS plans three-year contingent income autocallables linked to Amgen
|
4/13/2016 | SP | Credit Suisse plans autocallable reverse convertibles on Amgen stock
|
3/24/2016 | SP | New Issue: Wells Fargo prices $5.23 million of 0.125% notes tied to pharma stocks
|
3/22/2016 | SP | Wells Fargo to price 0.125% notes linked to four pharma stocks
|
3/21/2016 | SP | New Issue: Deutsche Bank prices $5.67 million one-year 9.9% securities on Amgen
|
2/23/2016 | BKIG | S&P rates Amgen bonds A
|
2/23/2016 | BKIG | Moody’s rates Amgen notes Baa1
|
2/23/2016 | BKIG | Fitch assigns BBB to Amgen notes
|
2/18/2016 | BKIG | S&P rates Amgen notes A
|
2/18/2016 | BKIG | Moody’s assigns Amgen notes Baa1
|
2/18/2016 | BK | Amgen to repay term loan borrowings via senior note offering proceeds
|
2/18/2016 | BKIG | Fitch rates Amgen notes BBB
|
2/2/2016 | SP | New Issue: Credit Suisse prices $919,000 8% autocallable buffered notes linked to Amgen
|
1/14/2016 | SP | New Issue: JPMorgan prices $8.8 million autocallable reverse exchangeables linked to pharma stocks
|
1/12/2016 | SP | New Issue: UBS prices $3.75 million of contingent income autocallables on Amgen
|
1/7/2016 | SP | UBS plans three-year contingent income autocallables linked to Amgen
|
1/6/2016 | SP | JPMorgan plans 10% autocallable reverse exchangeables linked to stocks
|
12/10/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Amgen
|
12/10/2015 | SP | New Issue: JPMorgan prices $2.3 million contingent income autocallable securities linked to Amgen
|
12/1/2015 | SP | JPMorgan plans contingent income autocallable securities on Amgen
|
10/29/2015 | SP | New Issue: Credit Suisse prices $1.4 million 8% autocallable reverse convertibles tied to Amgen
|
10/23/2015 | SP | New Issue: RBC prices $2.7 million bullish barrier enhanced notes on five stocks
|
10/20/2015 | SP | New Issue: RBC prices $410,000 bullish barrier enhanced notes linked to five stocks
|
10/19/2015 | SP | RBC plans 0% bullish barrier enhanced notes on basket of five stocks
|
10/15/2015 | SP | RBC plans bullish barrier enhanced return notes on five stocks
|
10/9/2015 | SP | New Issue: UBS prices $530,000 trigger phoenix autocallables linked to Amgen
|
10/5/2015 | SP | Credit Suisse plans autocallable reverse convertibles linked to Amgen
|
9/29/2015 | SP | New Issue: Morgan Stanley prices $3.63 million contingent income autocallable securities linked to Amgen
|
9/18/2015 | SP | Morgan Stanley plans contingent income autocallables linked to Amgen
|
9/16/2015 | SP | New Issue: Credit Suisse prices $1.75 million trigger phoenix autocallables linked to Amgen
|
9/9/2015 | SP | Credit Suisse to price trigger phoenix autocallables linked to Amgen
|
8/25/2015 | SP | New Issue: Morgan Stanley prices $5.95 million contingent income autocallable securities linked to Amgen
|
8/17/2015 | SP | Morgan Stanley plans contingent income autocallables linked to Amgen
|
7/15/2015 | BKIG | Fitch lifts Amgen to stable
|
7/8/2015 | SP | New Issue: UBS prices $211,000 return optimization securities linked to Amgen
|
6/16/2015 | SP | New Issue: UBS prices $395,000 trigger phoenix autocallables linked to Amgen
|
6/9/2015 | SP | New Issue: Barclays prices $1.41 million airbag phoenix autocallables linked to Amgen
|
6/3/2015 | SP | Barclays plans airbag phoenix autocallables linked to Amgen
|
6/1/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Amgen
|
5/28/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Amgen
|
5/15/2015 | SP | JPMorgan plans contingent income autocallables linked to Amgen
|
5/13/2015 | SPSW | May kicks off on good note with $446 million priced in 112 offerings; agents sell repeat deals
|
5/12/2015 | SP | New Issue: Credit Suisse prices $3.23 million trigger phoenix autocallables tied to Amgen
|
5/7/2015 | SP | Credit Suisse to price phoenix autocallables linked to Amgen
|
5/4/2015 | IG | Market Commentary: Morning Commentary: Amgen, Oracle bonds improve in early trade; strong supply on tap for week
|
5/1/2015 | EMHYMUPFPV | Market Commentary: Scotiabank adds on; Oracle bonds tighten; spreads mixed overall; busy May predicted
|
5/1/2015 | IG | Market Commentary: Scotiabank adds on; Oracle bonds tighten; spreads mixed overall; busy May predicted
|
4/29/2015 | EMHYMUPFPV | Market Commentary: United Technologies prices subordinated notes wide of talk; Oracle, Amgen bonds widen
|
4/29/2015 | IG | Market Commentary: United Technologies prices subordinated notes wide of talk; Oracle, Amgen bonds widen
|
4/28/2015 | EMHYMUPFPV | Market Commentary: Oracle brings $10 billion offering; Amgen, DaVinciRe also price; bank paper mostly flat
|
4/28/2015 | IG | Market Commentary: Oracle brings $10 billion offering; Amgen, DaVinciRe also price; bank paper mostly flat
|
4/28/2015 | BKIG | S&P assigns A to Amgen notes
|
4/28/2015 | IG | New Issue: Amgen sells $3.5 billion of senior notes in four tranches
|
4/28/2015 | BKIG | Moody's rates Amgen notes Baa1
|
4/28/2015 | BKIG | Fitch applies BBB to Amgen notes
|
4/28/2015 | IG | Amgen expected to price four-part offering of senior notes
|
4/14/2015 | SP | New Issue: Citigroup prices $5.91 million 6.65% airbag autocallables on Amgen
|
4/7/2015 | SP | Citigroup to price 6%-7% airbag autocallables linked to Amgen
|
3/30/2015 | SP | New Issue: JPMorgan prices $8 million 10% autocallable reverse exchangeables on three pharma stocks
|
2/24/2015 | SP | New Issue: Deutsche Bank sells $1.96 million airbag phoenix autocallables on Amgen
|
2/18/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Amgen
|
2/18/2015 | SP | Deutsche Bank plans airbag phoenix autocallables linked to Amgen
|
2/18/2015 | SP | New Issue: JPMorgan prices $11.04 million contingent income autocallable securities linked to Amgen
|
2/17/2015 | SP | New Issue: UBS prices $149,600 trigger phoenix autocallables linked to Amgen
|
2/6/2015 | SP | New Issue: UBS prices $249,810 5.43% trigger yield optimization notes on Amgen
|
2/6/2015 | SP | JPMorgan plans contingent income autocallables linked to Amgen
|
1/13/2015 | SP | New Issue: RBC prices $1.99 million contingent absolute return autocallables linked to Amgen
|
1/5/2015 | SP | RBC plans contingent absolute return autocallables linked to Amgen
|
12/30/2014 | SP | New Issue: Barclays prices $7.84 million autocallable notes linked to three pharmaceutical stocks
|
12/29/2014 | SP | Barclays plans autocallable notes tied to three pharmaceutical stocks
|
12/1/2014 | SP | New Issue: JPMorgan prices $3.45 million 7.25% reverse exchangeables linked to Amgen
|
11/17/2014 | IG | Market Commentary: Morning Commentary: High-grade credit spreads flat ahead of issuance; Citigroup, Amgen soft
|
11/7/2014 | BKIG | Moody’s changes Amgen to stable
|
9/10/2014 | SP | New Issue: Morgan Stanley prices $4.49 million worst of autocallables linked to four stocks
|
9/5/2014 | SP | Morgan Stanley plans worst-of autocallables linked four stocks
|
7/30/2014 | BK | Amgen enters into $2.5 billion amended revolving credit agreement
|
5/30/2014 | SP | New Issue: Barclays prices $2.23 million trigger autocallables linked to Amgen
|
5/29/2014 | SP | New Issue: Barclays prices $1 million 12.5% autocallable notes on three securities
|
5/20/2014 | SP | Barclays plans trigger autocallable notes linked to Amgen
|
5/19/2014 | BK | Amgen may repay term loan debt with proceeds of new notes
|
5/19/2014 | IG | S&P gives A to Amgen notes
|
5/19/2014 | BKIG | Fitch rates Amgen notes BBB
|
5/19/2014 | IG | Market Commentary: Amgen brings $4.5 billion; Nasdaq prices wide; DirecTV tightens; AT&T mostly better
|
5/19/2014 | BKIG | Moody's assigns Amgen notes Baa1
|
5/19/2014 | IG | New Issue: Amgen prices $4.5 billion of senior notes in five tranches
|
5/19/2014 | IG | Amgen pricing benchmark five-part offering of senior notes Monday
|
5/19/2014 | IG | Market Commentary: Midday Commentary: Investment-grade spreads unchanged; JPMorgan flat; AT&T better
|
5/15/2014 | SP | Barclays to price one-year autocallable notes linked to three stocks
|
5/6/2014 | SP | New Issue: Deutsche Bank prices $3.33 million trigger phoenix autocallables linked to Amgen
|
5/1/2014 | SP | Deutsche Bank plans trigger phoenix autocallables linked to Amgen
|
12/31/2013 | CV | Outlook 2014: U.S. primary market looks stronger after 'turning a corner' in Q4; terms may cheapen
|
12/30/2013 | SP | New Issue: Morgan Stanley prices $4.36 million worst-of autocallables linked to four stocks
|
12/24/2013 | SP | Morgan Stanley plans worst of autocallables linked to four stocks
|
10/22/2013 | SP | New Issue: Barclays prices $1.21 million trigger phoenix autocallables on Amgen
|
10/17/2013 | SP | Barclays plans trigger phoenix autocallable notes linked to Amgen
|
9/20/2013 | BK | Amgen obtains $5 billion term loan facility at Libor plus 100 bps
|
8/27/2013 | BKIG | Fitch: Amgen view to negative
|
8/27/2013 | BKIG | S&P cuts Amgen, debt to A
|
8/26/2013 | BKIG | Amgen plans $8.1 billion of bank loans to finance Onyx acquisition
|
8/26/2013 | CVIG | Moody's: Amgen view negative
|
5/21/2013 | SP | New Issue: UBS prices $475,500 trigger phoenix autocallable notes linked to Amgen
|
5/16/2013 | SP | UBS plans trigger phoenix autocallable securities linked to Amgen
|
2/4/2013 | CV | Market Commentary: Gilead Sciences steady ahead of earnings; Medtronic active; SandRidge lower on trust news
|
1/22/2013 | CV | Market Commentary: Amgen paper busy, higher as maturity nears; International Gaming firms after earnings
|
1/15/2013 | CV | Market Commentary: Amgen sees sellers ahead of maturity; Gilead Ds better; Lennar slips; Pacira to price
|
1/14/2013 | CV | Market Commentary: Dendreon adds outright; InterMune intends to price notes, shares; Lennar earnings on tap
|
1/8/2013 | CV | Market Commentary: Convertibles firm despite mixed underlying shares; short-dated, yield names strengthen
|
12/24/2012 | CV | Market Commentary: Convertibles quiet in shortened, pre-holiday session; Greatbatch trades higher on call
|
12/3/2012 | CV | Market Commentary: Teva trades after disappointing outlook; Volcano's planned $350 million convertible on tap
|
11/30/2012 | CV | Market Commentary: VeriSign drops outright in active trade but improves on hedge; larger, liquid names active
|
11/29/2012 | CV | Market Commentary: New Meritor trades flat despite higher shares; exiting Meritor active; Amgen up on hedge
|
10/23/2012 | CV | Market Commentary: RadioShack strengthens with buyback news; Gilead 'up small' ahead of earnings; AMD lower
|
10/2/2012 | CV | Market Commentary: WellPoint adds in the gray, models attractively; Molina, Amerigroup quiet; Illumina eyed
|
9/25/2012 | CV | Market Commentary: GT Advanced Technologies lifts despite lower shares; Navistar drops; Amgen, Gilead active
|
9/24/2012 | CV | Market Commentary: Planned GT Advanced looks cheap, lacks borrow; Suntech Power off from highs; Amgen active
|
9/10/2012 | BKCVIG | Fitch rates Amgen notes BBB
|
9/10/2012 | BKCVIG | S&P rates Amgen notes A+
|
9/10/2012 | BKCVIG | Moody's rates Amgen notes Baa1
|
9/7/2012 | CV | Market Commentary: Intel trades mixed to little changed after warning; NextEra adds 0.5 point dollar neutral
|
9/5/2012 | CV | Market Commentary: Toll Brothers trades unchanged on debut; Medicis in another 0.125 point; IG names active
|
8/31/2012 | CV | Market Commentary: Convertibles mostly flat for week; some see mixed performance for month, but indices gain
|
8/24/2012 | CV | Market Commentary: Convertibles mostly quiet; Gilead comes in slightly; Vertex static; Endo moves up a little
|
7/27/2012 | CV | Market Commentary: Amgen in line to slightly lower on earnings; Gilead, Coinstar in line as well; Amarin off
|
7/19/2012 | CV | Market Commentary: Amgen keeps tracking higher with shares; Xilinx gains on hedge; Kodak retakes 20; AMR up
|
7/5/2012 | CV | Market Commentary: Convertibles market quiet; Navistar steady before conference call; Patriot Coal around 30
|
6/27/2012 | CV | Market Commentary: High-grade names in focus; Lennar adds; Isis under pressure; Gevo to price $30 million
|
5/31/2012 | BKCVIG | S&P lifts health companies
|
5/11/2012 | IG | New Issue: Amgen prices $3 billion of notes in five-, 10-, 31-year tranches
|
5/11/2012 | IG | Market Commentary: Amgen, Sweden give terms; $25 billion or more expected in coming week; bank paper widens
|
5/10/2012 | CVIG | S&P rates Amgen notes A+
|
5/10/2012 | IG | Market Commentary: Amgen, Discovery, Beam do multi-tranche sales as tone rebounds; Beam tightens; banks improve
|
5/10/2012 | CVIG | Fitch rates Amgen bonds BBB
|
5/10/2012 | CVIG | Moody's rates Amgen notes Baa1
|
4/27/2012 | CV | Market Commentary: Amgen adds 0.25 point on hedge; Micron C notes weaker, but catches bid; Chesapeake pressured
|
4/24/2012 | CV | Market Commentary: Amgen trades little changed ahead of earnings; U.S. Steel slips; Tibco outperforms shares
|
4/11/2012 | CV | Market Commentary: New DFC Global rises to 104 on debut; new Prospect reoffered at 97.75; Micron launches
|
4/4/2012 | CV | Market Commentary: SanDisk 1.5% convertibles come in on hedge; NetApp trades in line; Western Refining adds
|
3/27/2012 | CV | Market Commentary: Lennar flat to slightly higher on hedge on earnings; Radian steady; Dendreon catches a bid
|
3/22/2012 | CV | Market Commentary: Shares of planned Cenveo plunge ahead of pricing; Amgen, Vornado, A123 Systems edge lower
|
3/13/2012 | CV | Market Commentary: New Salix pops, then retreats on debut; Medivation talk revised; Wintrust notes to price
|
2/13/2012 | CV | Market Commentary: Regeneron jumps after boosting sales outlook; Beazer launches exchange; iStar unchanged
|
2/10/2012 | CV | Market Commentary: Alcatel-Lucent up on strong earnings; Gilead, Amgen mixed on hedged basis; Siemens prices
|
2/8/2012 | CV | Market Commentary: Gilead edges up further on swap; RadioShack steady; Hutchinson jumps; solar names in focus
|
1/18/2012 | CV | Market Commentary: Amgen, Gilead improve on hedge; D.R. Horton, Synnex trade mostly in line; Cheniere slips
|
1/17/2012 | CV | Market Commentary: Life Technologies rises in active trading on call news; Amgen busy; Kingross loses ground
|
1/13/2012 | CV | Market Commentary: Patriot coal announces production cuts; coal sector suffers; Amgen 'big trading name'
|
1/9/2012 | CV | Market Commentary: Convertibles revert to 'quiet'; Alcoa firm to better ahead of earnings; Amgen steady
|
12/23/2011 | CV | Market Commentary: SunPower jumps on Total transactions; PHH slips further; market quiet ahead of holiday
|
12/21/2011 | CV | Market Commentary: Convertibles quiet; Salesforce better dollar neutral; Micron reports disappointing loss
|
12/20/2011 | CV | Market Commentary: Jefferies recoups, moves higher with positive earnings; Navistar looks better on earnings
|
12/19/2011 | CV | Market Commentary: Amgen edges higher; Gilead mixed to higher; Jefferies lower; MF Global adds a few points
|
12/5/2011 | BK | Amgen enters into new $2.5 billion five-year revolving facility
|
11/30/2011 | CVIG | S&P rates Amgen notes A+
|
11/30/2011 | CVIG | Moody's: Amgen notes Baa1
|
11/29/2011 | CV | Market Commentary: AMR collapses after bankruptcy filing; Transocean Cs improve; Onyx seen lower on hedge
|
11/21/2011 | IG | Market Commentary: IBRD reopens short bond, volatility halts issuance; financials trade wider in light volume
|
11/14/2011 | CVIG | Fitch rates Amgen bonds BBB
|
11/8/2011 | IG | New Issue: Amgen prices $6 billion of senior notes in four tranches
|
11/8/2011 | IG | Market Commentary: International Paper brings $1.5 billion; Halliburton sells $1 billion; HP firms; Hershey flat
|
11/7/2011 | CVIG | Moody's cuts Amgen
|
11/7/2011 | CVIG | S&P rates Amgen notes A+
|
11/7/2011 | IG | Amgen to offer $6 billion of senior notes in four tranches
|
11/7/2011 | CV | Market Commentary: Jefferies adds after unwinding euro debt; Amgen unmoved on share buyback, debt deal
|
11/7/2011 | IG | Market Commentary: Canadian Railway, Zimmer bring deals; Jefferies bucks sector weakness; telecom bonds widen
|
11/7/2011 | CVIG | Fitch downgrades Amgen
|
10/25/2011 | CV | Market Commentary: Convertibles weaken with equity slump; MF Global 'gets smoked' on earnings disappointment
|
10/25/2011 | CVIG | Moody's: Amgen view negative
|
10/24/2011 | CV | Market Commentary: Convertibles rise on light volume; Radian up; hedged players lose on RightNow's Oracle offer
|
10/21/2011 | CV | Market Commentary: SanDisk moves up on positive earnings; Old Nuance opens up; Investment-grade names active
|
10/20/2011 | CV | Market Commentary: Cubist improves dollar neutral; Ingersoll-Rand drops; low-premium names 'better for sale'
|
10/13/2011 | CV | Market Commentary: Clearwire extends gains on positive quarterly figures; United Therapeutics paper unchanged
|
10/4/2011 | CV | Market Commentary: DryShips' convertibles slip; Overall market hit by weakness; MGM falls; AMR rallies
|
9/30/2011 | CV | Market Commentary: Convertibles sell off; GMX, MGM trade lower; Kodak drops sharply on restructuring fears
|
9/29/2011 | CV | Market Commentary: Kodak extends losses even as stock rises; AMD slips, shares plunge; Cemex trades in line
|
9/16/2011 | CV | Market Commentary: Textron climbs on takeover talk; Alcoa benefits from tender hopes; Amgen, Genco active, flat
|
9/15/2011 | CV | Market Commentary: Suntech, JA Solar fall on downgrades; InterMune continues rising; EMC, Amgen climb higher
|
9/12/2011 | CV | Market Commentary: Global Industries surges on takeover offer; Hornbeck up 2-3 points; Clearwire weakens
|
8/31/2011 | CV | Market Commentary: Convertibles better; EMC, MF Global gain; stabilizing markets point to better September
|
8/24/2011 | CV | Market Commentary: Hedge players win on United Therapeutics; Amerigroup adds; investment-grade paper active
|
8/22/2011 | CV | Market Commentary: Kodak adds premium points; Clearwire steady at higher levels; Medtronic, Amgen, EMC firm
|
8/19/2011 | CV | Market Commentary: Salesforce up on earnings; hedged Micron beats tech woes; Amgen, EMC see flight to quality
|
8/12/2011 | CV | Market Commentary: Convertibles firm slightly; Tyson, United Rentals recouping; Microsoft little changed
|
8/11/2011 | CV | Market Commentary: High-grade paper mixed as strong equity rally cools convertibles; Bank of America in focus
|
7/18/2011 | CV | Market Commentary: Convertibles weak; Endeavour sells $120 million deal; WebMD collapses on lowered guidance
|
7/15/2011 | CV | Market Commentary: Electronic Arts opens higher on strong demand, rich pricing; Intel, AMD trade before earnings
|
7/12/2011 | CV | Market Commentary: Convertibles fall; Europe fears build with Ireland's downgrade; volumes low amid volatility
|
7/1/2011 | IG | Market Commentary: Second-quarter issuance starts strong, ends weak; trading slows; financials, new bonds firm
|
6/29/2011 | CV | Market Commentary: Liquid names in trade; U.S. Steel lags underlying shares; Cameron trades ahead of call
|
6/28/2011 | IG | Market Commentary: HSBC, National Retail sell as Greece austerity vote looms; Nokia 15 bps better; telecoms firm
|
6/27/2011 | CVIG | Moody's rates Amgen notes A3
|
6/27/2011 | CVIG | Fitch rates Amgen notes A-
|
6/27/2011 | IG | New Issue: Amgen prices $3 billion of five, 10-, 31-year senior notes
|
6/27/2011 | IG | Market Commentary: Amgen monster deal, Carpenter, Kilroy among those in volatile primary; Amgen long bonds wider
|
6/27/2011 | CVIG | S&P rates Amgen notes A+
|
5/19/2011 | CV | Market Commentary: Amgen active around 101; Molson Coors, Lam Research trade at steady pricing; WebMD adds
|
5/3/2011 | CV | Market Commentary: Mylan off outright, expands on hedge; Incyte premium comes in; Alaska Communications on tap
|
5/3/2011 | CVIG | Fitch cuts Amgen
|
4/28/2011 | CVIG | Moody's cuts Amgen to stable
|
4/20/2011 | CV | Market Commentary: EMC gains on earnings; Textron slips on miss; Amgen up ahead of report; Amylin continues rally
|
3/4/2011 | CVIGPF | Amgen files automatic shelf for stock, preferreds and debt securities
|
3/1/2011 | CVIG | Fitch affirms Amgen
|
2/16/2011 | CV | Market Commentary: Convertibles lackluster; Ciena trades mixed to higher; Radian gains; USEC mostly unchanged
|
2/4/2011 | CV | Outright convertible players add 1.9% for January, Citigroup says
|
2/2/2011 | CV | Market Commentary: EMC, Amgen paper steady to higher; Savient extends gains; D.R. Horton, Lennar in trade
|
1/25/2011 | CV | Citi says replace $15 billion of maturing converts with AngloGold, Boston Properties, among others
|
1/24/2011 | CV | Market Commentary: Salesforce.com under pressure; RadioShack lower; Molycorp plans mandatory; Nielsen on tap
|
1/21/2011 | CV | Market Commentary: Amgen, Micron convertibles higher dollar neutral; AMR slips; NovaMed gains on takeout
|
12/14/2010 | CV | Market Commentary: Amgen jumps in line on positive drug news; Transocean active; Home Inns prices; Swift on tap
|
12/7/2010 | CV | Market Commentary: Wintrust holds up amid lower shares; Evergreen active; UBS-Stillwater exchangeable on tap
|
11/24/2010 | CV | Market Commentary: Convertibles quiet ahead of Thanksgiving as positive data lifts shares; investors cautious
|
11/23/2010 | CV | Market Commentary: Convertibles take hit as shots fly between North, South Korea; market quiet before holiday
|
11/1/2010 | SP | New Issue: Credit Suisse prices $1.5 million contingent coupon autocallable notes linked to five stocks
|
10/27/2010 | CV | Market Commentary: Digital River gains on debut; Equinix higher, in line; Energy XXI, Green Plains on tap
|
10/21/2010 | SP | Credit Suisse plans contingent coupon callable notes on five stocks
|
10/7/2010 | CV | Market Commentary: Amgen steady in active trade; Equinix continues to expand after warning; Alcoa quiet
|
9/23/2010 | CV | Market Commentary: Vertex Pharma adds on active debut; Avis, Hertz slip; Rite Aid down, but CBIZ adds to debut
|
9/15/2010 | IG | Market Commentary: Cliffs Natural, Blackstone, Harsco, JPMorgan, Wyndham among sellers; Amgen notes widen
|
9/13/2010 | CV | Market Commentary: Hertz comes 'in' a little on swap with better Dollar Thrifty bid; Level 3, Volcano on tap
|
9/13/2010 | IG | Market Commentary: Amgen, Symantec bring billion-dollar deals as offerings stack up; HP, Dell 10 bps better
|
9/13/2010 | CVIG | S&P rates Amgen notes A+
|
9/13/2010 | CVIG | Moody's rates Amgen notes A3
|
9/13/2010 | CVIG | Fitch rates Amgen notes A
|
9/13/2010 | IG | Amgen to price $1.5 billion in 10-, 30-year senior unsecured notes
|
9/13/2010 | IG | New Issue: Amgen prices $1.5 billion 10-, 31-year senior notes
|
9/10/2010 | CV | Market Commentary: UBS' new GT Solar mandatories slip below par on debut; Amgen trades in line with shares
|
7/30/2010 | CV | Market Commentary: A&P bonds recoup some losses; Gilead flat; Virgin Media slips; issuance tracks 2009 pace
|
7/29/2010 | CV | Market Commentary: Symantec, CommScope improve despite weak quarterly results; Life Technologies paper better
|
7/7/2010 | CV | Market Commentary: FTI Consulting richens despite revised outlook; Affymetrix steady; EMC gains after upgrade
|
7/2/2010 | CV | Market Commentary: Convertibles quiet; Lincare A paper improves dollar neutral; Informatica up; Helix firm
|
7/1/2010 | CV | Market Commentary: Amgen, Medtronic, Transocean trade in high volumes; ProLogis mixed; Ford price fluctuates
|
6/24/2010 | CV | Market Commentary: Shorter-dated high-grade names in trade; Transocean, Medtronic, Symantec in line; PPL up
|
6/21/2010 | CV | Market Commentary: Biovail gains on merger with Valeant; Amgen up on competitor's drug safety; PPL on tap
|
6/17/2010 | SP | New Issue: Barclays prices $360,000 10.5% callable reverse convertibles on Amgen
|
6/4/2010 | CVIG | Moody's: Amgen outlook positive
|
6/4/2010 | CV | Market Commentary: Convertibles weaken; Xilinx trades down on debut; Transocean, Amgen improve, then decline
|
6/2/2010 | CV | Market Commentary: Transocean extends fall, then bounces; Cameron steadies; Amgen sideways; REITs active
|
5/21/2010 | CV | Market Commentary: Convertibles unsteady; Amgen, Omnicare lower; Cemex firms; Symmetricom buying 3.25% notes
|
5/6/2010 | CV | Market Commentary: Equities plummet, then partially recover; some convertibles buyers step in after decline
|
4/23/2010 | CV | Market Commentary: Health care names recover; investment-grade names in focus; Incyte, Textron strengthen
|
4/21/2010 | CV | Market Commentary: MGIC soars on debut; Evergreen Solar active on new issue, tender; Gilead Sciences improves
|
4/12/2010 | CV | Market Commentary: Convertibles mixed; Transocean, Beckman active; ON Semi's 0s add on incentive; Quanta off
|
3/9/2010 | CVIG | Moody's gives Amgen notes A3
|
3/9/2010 | CVIG | Fitch affirms Amgen
|
3/9/2010 | IG | New Issue: Amgen sells $1 billion of senior notes in 10-, 30-year tranches
|
3/9/2010 | IG | Market Commentary: Novartis, Amgen, Anadarko, ProLogis, RBS among IG issuers; new deals firm in busy trading day
|
3/9/2010 | CVIG | S&P assigns Amgen notes A+
|
2/25/2010 | CV | Market Commentary: Convertibles volume thin; CSG edges up on debut; Newmont Mining mixed, Capital Source quiet
|
2/19/2010 | CV | Market Commentary: Convertibles higher outright, but quiet; Amgen steady; Trico Marine down; LifePoint weaker
|
1/25/2010 | CV | Market Commentary: EMC extends losses ahead of earnings; Amgen, Boston Properties little changed; UAL drops
|
1/15/2010 | CV | Market Commentary: SanDisk, Bunge up on yield trades; Micron Technology slips with stock; Incyte down, active
|
1/15/2010 | SP | New Issue: JPMorgan prices $2.2 million 9.25% upside auto callable reverse exchangeables on Amgen
|
1/7/2010 | CV | Market Commentary: Beazer Homes trades up with shares on debut; Alcoa weaker; Boston Properties active, steady
|
1/4/2010 | CV | Market Commentary: Big cap, investment-grade names dominate convertibles trading: Amgen adds, Transocean mixed
|
12/11/2009 | SP | New Issue: Barclays prices $1 million 11% reverse convertibles linked to Amgen
|
10/30/2009 | CV | Market Commentary: Amgen trades mixed after lawsuit news; Kodak quiet but still losing ground; AMR extends slide
|
10/5/2009 | CV | Market Commentary: UAL adds amid quiet trading; AMD gains; Medtronic up in solid volume; trading breadth narrow
|
9/28/2009 | CV | Market Commentary: Convertibles quiet; AMR steady; Newmont strengthens; Aspect Medical change of control eyed
|
9/22/2009 | CV | Market Commentary: AMR adds in gray, then upsizes; MannKind gains more: Goodrich, ATP, Incyte, Gaylord to price
|
9/21/2009 | CV | Market Commentary: AMR launches convertible; Amgen, MannKind, Nektar active in trade; Sonic, Kodak richen
|
9/18/2009 | CV | Market Commentary: Kodak, Sonic issues gain on debuts; older paper higher; Newmont rises; D.R. Horton strong
|
9/1/2009 | CV | Convertibles return nearly 4% for August, marking sixth straight positive month: Barclays Capital
|
8/27/2009 | CV | Market Commentary: NCI Building jumps on sweetened exchange; International Game gains; players eye primary
|
8/17/2009 | CV | Market Commentary: AMD, Intel, EMC lower as techs falter; Newmont slips with gold; Amgen declines with stock
|
7/27/2009 | CV | Market Commentary: Ford careens higher; Webster boosted by PIPE investment; Mylan mostly firm as shares drop
|
7/13/2009 | CV | Market Commentary: CIT loses more as liquidity worries go on; BofA, other financials improve; Vale, SBA trade
|
7/8/2009 | CV | Market Commentary: Amgen trades actively on positive trial news; Equinix dips but pares losses; Vale edges up
|
7/6/2009 | CV | Market Commentary: Investment-grade names attract buyers, improve; St. Mary Land active; Vale, Regis to price
|
6/24/2009 | CV | Market Commentary: Rambus convertibles add in quiet debut; LodgeNet quiet; PNC up as investors eye safety play
|
6/11/2009 | CV | Market Commentary: Amgen B paper active, lower; Alcoa nears double par; B of A extends gains; EMC, NetApp eyed
|
5/20/2009 | CV | Market Commentary: FPL trades steady to slightly lower on debut; Hertz gains in gray; Cephalon launches deal
|
4/29/2009 | CV | Market Commentary: U.S. Steel, SunPower gain on debuts; Textron moves up in gray; Qwest edges up, but UAL slips
|
2/26/2009 | CV | Market Commentary: Fifth Third, Huntington gain as financials rally; Sallie Mae, Amgen, Hologic decline on budget details
|
2/20/2009 | CVIG | Fitch affirms Amgen
|
1/26/2009 | CV | Market Commentary: Convertibles little changed: Wyeth steady on Pfizer deal; Amgen active ahead of earnings; AMD gains
|
1/21/2009 | CV | Market Commentary: Financial preferreds bounce a little from big drop; health care, biotech names in trade; Avnet edges higher
|
1/14/2009 | IG | New Issue: Amgen gives terms for $2 billion of notes in 10-, 30-year tranches
|
1/14/2009 | IG | Market Commentary: High volume continues: CSX, Pepsi unit, Campbell Soup, R.R. Donnelley, Morgan Stanley price
|
1/13/2009 | IG | New Issue: Amgen prices $2 billion of notes in 10-, 30-year tranches
|
1/13/2009 | IG | Market Commentary: Hectic day sees FedEx, Amgen, Reed Elsevier, McDonald's, Goldman, others price; Citi, Morgan Stanley wider
|
1/13/2009 | CVIG | S&P rates Amgen notes A+
|
1/13/2009 | CVIG | Fitch gives Amgen notes A
|
1/13/2009 | CVIG | Moody's gives Amgen notes A3
|
1/9/2009 | CV | Market Commentary: Convertibles little changed: NatCity, Amgen active but off week's highs; bank convertibles mixed
|
1/7/2009 | CV | Market Commentary: Amgen, Medtronic succumb to profit taking; Intel up; Liberty/Time Warner in line despite warnings
|
1/6/2009 | CV | Market Commentary: Convertibles add on stronger volume: Sprint/Nextel, NII Holdings, Alliant Techsystems strengthen
|
12/18/2008 | CV | Market Commentary: Convertibles stronger: Mylan adds 0.5 point; strong bid on IG names; Allergan 1.5% notes up to par
|
12/15/2008 | CV | Market Commentary: Convertibles mostly quiet; iStar Financial floaters little changed; Mylan weaker; Amgen strengthens
|
12/9/2008 | CV | Market Commentary: Ford, GM mixed to lower pending bill; Amgen eases; Fifth Third Bancorp, ON Semiconductor weaker
|
11/14/2008 | CV | Market Commentary: Convertibles mixed: EMC better; Amgen little changed to lower; Transocean wavers on weaker oil
|
11/5/2008 | CV | Market Commentary: Chesapeake gains on renewed takeover rumors; Bunge firms on merger headwinds; Amgen, Ford decline
|
11/3/2008 | CV | Market Commentary: Virgin Media jumps on bank amendment; Ford unmoved by weak sales; Amgen, Medtronic up with stocks
|
10/28/2008 | CV | Market Commentary: Equities boost convertibles; Vornado, Amgen climb; KeyCorp rises on TARP nod; Transocean still soft
|
10/15/2008 | CV | Market Commentary: Low bids drag convertibles lower; Sallie Mae, Virgin Media retrace gains; Amgen convertibles better
|
10/1/2008 | CV | Market Commentary: Convertible price dislocations plague market; Ford, Amgen off; ImClone little moved; Fannie Mae at parity
|
9/16/2008 | CV | Market Commentary: AIG future hangs in the balance; Wachovia retraces some losses; Amgen convertibles up on drug data
|
8/13/2008 | CVIG | S&P: Amgen outlook stable
|
7/28/2008 | CV | Market Commentary: Amgen gains on clinical results; financials weaker; new XM Satellite deal looks cheap; XL, PSS to price
|
7/25/2008 | CV | Market Commentary: Affymetrix down on quarterly loss; Amgen steady pre-earnings; Countrywide bondholders eye angles
|
7/2/2008 | CV | Market Commentary: Smithfield Foods jumps to 103 on debut; GM, Ford slide; Coal names drop with stocks; Amgen adds
|
5/29/2008 | IG | S&P: Amgen unaffected
|
5/21/2008 | IG | Market Commentary: ING, ILFC, Liberty Mutual, NYSE price; Amgen takes opportunity to go long; secondary softens
|
5/20/2008 | CVIG | Fitch rates Amgen notes A
|
5/20/2008 | IG | New Issue: Amgen prices $1 billion senior notes in 10-, 30-year tranches
|
5/20/2008 | IG | Market Commentary: Amgen, Bank of America, American Express unit price; low new issue premiums cause secondary woes
|
5/20/2008 | CVIG | S&P gives Amgen notes A+
|
5/20/2008 | CVIG | Moody's gives Amgen notes A3
|
5/19/2008 | CV | Market Commentary: Huntington remains firm, but Sallie Mae weakens; Medtronic softer ahead of earnings, but Hologic adds
|
5/13/2008 | CV | Moody's lowers Amgen
|
5/13/2008 | IG | Moody's cuts Amgen
|
5/5/2008 | SP | Natixis to price 10% reverse convertibles linked to Amgen for Eksportfinans
|
4/17/2008 | CVIG | Amgen files automatic shelf registration
|
4/10/2008 | CV | Market Commentary: Endo jumps on debut; takeout news lifts Millenium, other biotechs gain; NatCity in play
|
4/7/2008 | SP | Barclays to price 9% reverse convertibles linked to Amgen
|
4/3/2008 | CV | Fitch rates Amgen A
|
3/17/2008 | IG | Moody's may cut Amgen
|
3/13/2008 | CV | Market Commentary: Newmont Mining, Amgen gain; Coeur d'Alene adds on debut; Aspect Medical slumps
|
3/10/2008 | CV | Market Commentary: Convertible bonds weaken; Countrywide down 3 points; Level 3, Merrill active
|
2/22/2008 | CV | Market Commentary: Silver Standard muted on debut; EMC slips with stock; Amgen, Level 3 lower as markets end mixed
|
1/24/2008 | CV | Market Commentary: Bank of America removes the juice; National City opens flat; Kinross Gold sparkles
|
12/21/2007 | CVIG | Moody's rates Amgen loan A2
|
12/7/2007 | CV | Market Commentary: Prudential opens lower; Transocean stays active; Macrovision sinks on Gemstar-TV Guide deal
|
10/31/2007 | SP | New Issue: ABN Amro sells $1 million 12% Knock-in Reverse Exchangeables linked to Amgen
|
10/23/2007 | CV | Market Commentary: Level 3 hammered on earnings; Countrywide down on borrower bailout; Medtronic coming back?
|
10/5/2007 | CV | Market Commentary: Molina opens strong; Eastman Kodak, Symantec, Amgen, Level 3, Best Buy all up; EMC mixed
|
10/2/2007 | SP | ABN Amro to price 12% reverse exchangeables linked to Amgen
|
10/2/2007 | CV | Market Commentary: Ford convertibles rise as sales fall; GM up; EMC continues strong show; Amgen slips; CapLease launches new issue
|
9/12/2007 | CV | Market Commentary: Countrywide holds steady; XM up on merger speculation; Calpine rocked some more; usual suspects rounded up
|
9/7/2007 | CVIG | S&P affirms Amgen
|
8/30/2007 | SP | New Issue: RBC prices $395,000 8.45% reverse convertibles linked to Amgen
|
8/29/2007 | SP | New Issue: UBS prices $1.39 million 8.78% yield optimization notes linked to Amgen
|
8/24/2007 | CV | Market Commentary: Anthracite opens quietly, doesn't provide good test; Ford, Intel, Yahoo!, Peabody up; Amgen nudges down
|
8/22/2007 | CV | Market Commentary: Countrywide continues recovery; Amgen, BioMarin nudge up; Ford edges down; market mayhem 'dying down'
|
8/15/2007 | CV | Market Commentary: Countrywide, KKR Financial fall; VeriSign starts strong; Amgen slips; wider markets fall on news
|
8/8/2007 | SP | RBC to price 8.45% reverse convertibles linked to Amgen
|
7/31/2007 | CV | Market Commentary: RAIT Financial Trust, KKR Financial tumble; AmeriCredit stumbles; mortgage-linked convertibles dive
|
7/27/2007 | CV | Market Commentary: Medtronic, Amgen, EMC all active as investors run for cover; trading volume stays high
|
7/26/2007 | SP | UBS to price yield optimization notes linked to Amgen
|
6/26/2007 | CV | Market Commentary: Gannett jumbo deal, GSI issue on tap; Huntsman surges on merger; Amgen slides; Medtronic rises
|
6/8/2007 | CV | Market Commentary: Bausch & Lomb unmoved by fading hopes of rival offer; Amgen, Intel, Ford recover; market still cautious
|
6/5/2007 | CV | Market Commentary: Amylin gains on debut; Integra higher, Ciena, Dendreon quiet in gray; Cogent, Panda launch unusual deals
|
5/23/2007 | CV | S&P: Amgen on watch
|
5/23/2007 | CV | Moody's cuts Amgen view to negative
|
5/22/2007 | SP | New Issue: JPMorgan prices $0.65 million 9% reverse exchangeables linked to Amgen
|
5/17/2007 | SP | JPMorgan to price 9% reverse exchangeables linked to Amgen
|
5/15/2007 | CV | Market Commentary: Amgen holds firm; Ford gains on deal; Gold Reserve up on debut; NPS, Shuffle Master see takeout hopes
|
5/11/2007 | CV | Market Commentary: CACI climbs in debut; L-1 rises despite borrow concerns; Amgen slips further; Conseco gains on sentiment
|
5/10/2007 | CV | Market Commentary: Amgen falls under drug panel scrutiny; Alesco, Chesapeake gain early, end flat; CACI, L-1 quiet in gray
|
4/27/2007 | SP | New Issue: RBC sells $305,000 7.5% reverse convertibles linked to Amgen
|
4/16/2007 | SP | RBC to price 7.5% reverse convertibles linked to Amgen
|
4/2/2007 | CV | Market Commentary: Cephalon improves on FDA letter; Amgen remains soft on safety risks; issue pipeline seen healthy
|
3/15/2007 | CV | Market Commentary: Stanley Works sprints off the blocks; Amgen retreats on Medicare review; Alpharma bright in gray market
|
3/9/2007 | CV | Market Commentary: PrivateBancorp gains on strong demand; West Pharmaceutical quiet on debut; Amgen slips on new labels
|
3/5/2007 | CV | Market Commentary: CompuCredit falls on sector troubles; Amgen gains on upgrade; EMC drops with stock; Barnes plans deal
|
3/2/2007 | CV | Amgen holders put $8.9 million LYONs, $2.24 billion zero-coupon convertibles
|
3/1/2007 | CV | Market Commentary: Amgen slips on inquiry, drug concerns; Gilead firms on trial results; Hospitality Properties absent in gray
|
1/29/2007 | CV | Market Commentary: Bristol-Myers gains amid takeover talk; Sunpower distribution could be tight; Amgen continues decline
|
1/26/2007 | CV | Market Commentary: Covanta takes off on debut; Halliburton drops on results, confusion; Amgen lower on earnings, drug data
|
1/22/2007 | CV | Market Commentary: Amgen gains on dispute news; Ford rises before results; XM ignores stock slide; Lexington launches deal
|
1/4/2007 | CV | Market Commentary: Intel climbs on raised estimates; Amgen rallies on upgrade; 2007 could return 11%-11.5%, Lehman says
|
12/1/2006 | CV | Market Commentary: JDS Uniphase firm on sector concerns; Goodrich quiet in debut; Amgen, Gilead hit on broad pullback
|
11/6/2006 | BT | Merrill puts Amgen at neutral
|
10/24/2006 | BT | Amgen on hold by Jefferies
|
10/24/2006 | BT | Merrill maintains Amgen at neutral
|
10/23/2006 | BT | Amgen reports 15% revenue growth in Q3, expanded R&D focus
|
10/23/2006 | BT | Market Commentary: Connetics gains 46% on merger; Replidyne falls 45%, Forest down 6%; Adeza loses 16%; Amgen off
|
10/20/2006 | BT | Jefferies puts Amgen on hold
|
10/20/2006 | BT | Amgen kept at neutral by Merrill
|
10/20/2006 | BT | Market Commentary: BioVex IPO pulled; Ariad dives; Encysive off; Vical spikes 10%; Amgen higher ahead of results
|
10/19/2006 | BT | Amgen kept at neutral by Merrill
|
10/17/2006 | BT | Bear Stearns rates Amgen at peer perform
|
10/16/2006 | BT | Merrill keeps Amgen at neutral
|
10/16/2006 | BT | Market Commentary: Vical up on PIPE; Amgen sinks on FDA delay; Critical up 16%; Omrix off 14.5% on profit taking
|
10/3/2006 | BT | Merrill analyst says third-quarter biotech earnings could be mixed
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
9/28/2006 | BT | Jefferies puts Amgen on hold
|
9/28/2006 | BT | Amgen kept at neutral by Merrill
|
9/27/2006 | CV | Market Commentary: BearingPoint, Amkor slip on default woes; Red Hat falls outright with earnings; Brandywine plans deal
|
9/22/2006 | BT | Amgen at neutral by Merrill
|
9/22/2006 | BT | Market Commentary: Amgen leads sector lower; Dyax gains on Kos' loss; Oscient rises; Gene Logic up; Discovery Labs off
|
9/19/2006 | BT | Amgen: Denosumab antibody enhances bone-mineral density
|
9/19/2006 | BT | Amgen licenses '866 patent from Yeda
|
9/15/2006 | BT | Market Commentary: Vertex slips but deal a hit; Barrier, Auxilium rise on PIPEs deals; ImClone, Encysive, Arena higher
|
9/12/2006 | BT | Ariad: Court denies motion to dismiss Amgen patent lawsuit
|
8/4/2006 | BT | Amgen kept at neutral by Merrill
|
8/3/2006 | BT | Amgen erythropoietin patents infringed upon by Transkaryotic, Aventis, court says
|
7/31/2006 | BT | Predix, Amgen to collaborate on development of S1P1 modulators for autoimmune diseases
|
7/28/2006 | BT | Amgen kept at neutral by Merrill
|
7/21/2006 | BT | Bear Stearns reiterates Amgen at peer perform
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/21/2006 | CV | Market Commentary: Amgen climbs with earnings; Halliburton, Schlumberger slip outright; PMC-Sierra tumbles on loss
|
7/21/2006 | BT | Merrill maintains Amgen at neutral
|
7/21/2006 | BT | Amgen on hold by Jefferies
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/19/2006 | BT | Jefferies puts Amgen on hold
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
7/17/2006 | BT | Amgen to study cardiovascular effects of Sensipar/Mimpara on hyperparathyroidism patient with kidney disease
|
7/14/2006 | BT | Merrill keeps Amgen at neutral
|
7/13/2006 | BT | Market Commentary: Nastech loses 15% on FDA snub; Novavax retreats; Anadys moves up; Acadia slumps; Illumina lifted
|
7/10/2006 | BT | Amgen kept neutral by Merrill
|
6/26/2006 | CV | Market Commentary: Intel, Amgen under pressure; Inco rises; Chesapeake launches mandatories offering
|
6/21/2006 | BT | Bear Stearns maintains Amgen at peer perform
|
6/20/2006 | CV | Market Commentary: Medtronic, Amgen fall prey to selling pressure; JetBlue adds; Actuant plunges
|
6/19/2006 | BT | Amgen says Aranesp may decrease mortality in heart-failure patients with anemia
|
6/13/2006 | BT | Merrill keeps Amgen at neutral
|
6/13/2006 | BT | Amgen maintained at peer perform by Bear Stearns
|
6/12/2006 | BT | FDA grants priority review of Amgen's panitumumab for colorectal cancer
|
6/9/2006 | CV | Market Commentary: Advanced Medical brushes off Fitch downgrade; Gilead, Amgen, Trinity gain; L-3 unchanged
|
6/5/2006 | BT | Amgen says interim data points to benefit of Aranesp for chemotherapy-induced anemia
|
6/5/2006 | BT | Amgen reports 'major' response in phase 2 trial of Aranesp for myelodysplastic syndromes
|
6/5/2006 | BT | Jefferies keeps Amgen at hold
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/22/2006 | CV | Market Commentary: Transocean, Oil States slide on oil concerns; Amgen gains on upgrade; Cameron premium meets resistance
|
5/19/2006 | BT | Amgen at neutral by Merrill
|
5/18/2006 | BT | Amgen data shows Aranesp similar to Epoetin alfa
|
5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
5/11/2006 | BT | Amgen at neutral by Merrill
|
5/11/2006 | BT | Bear Stearns puts Amgen at peer perform
|
5/10/2006 | BT | Merrill rates Amgen at neutral
|
5/9/2006 | BT | ITC to investigate Amgen's complaint against Roche's Peg-EPO
|
5/5/2006 | BT | Market Commentary: Northstar Neuroscience stock climbs on upsized IPO; Praecis stock jumps 22.3% on earnings
|
5/5/2006 | CV | Market Commentary: Safenet gains on earnings, stock buyback; Scottish Re widens after poor quarter; Finisar flat after rally
|
4/27/2006 | BT | Amgen at neutral by Merrill
|
4/24/2006 | BT | Alcon, Amgen to collaborate on treatments for eye diseases
|
4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
4/21/2006 | BT | Market Commentary: Omrix settles above water but on deep-discount pricing; Affymetrix plunges 14%; Genitope gains 3%
|
4/19/2006 | BT | Amgen on hold by Jefferies
|
4/19/2006 | BT | Market Commentary: Genzyme crashes on miss; Nektar dips, ends higher; MannKind off; Icon better; Nabi adds another 4%
|
4/19/2006 | BT | Merrill maintains Amgen at neutral
|
4/18/2006 | BT | Amgen says adjusted 1Q06 EPS reaches $0.91, raises 2006 EPS guidance to $3.60-$3.70
|
4/18/2006 | BT | Amgen at hold by Jefferies
|
4/18/2006 | BT | Merrill rates Amgen at neutral
|
4/12/2006 | BT | Bear Stearns keeps Amgen at peer perform
|
4/12/2006 | BT | Amgen at neutral by Merrill
|
4/11/2006 | BT | Amgen asks trade commission to block import of peg-EPO by Roche
|
4/7/2006 | BT | Jefferies keeps Amgen at hold
|
4/6/2006 | BT | Market Commentary: Amgen a drag on biotech sector; Medarex follow-on seen on deck; Oscient up on PIPE after-hours
|
4/5/2006 | CV | Market Commentary: Conexant gains on report; ON Semiconductor up despite downgrade; Ciena struggles off the blocks
|
4/4/2006 | BT | Amgen maintained at neutral by Merrill
|
4/3/2006 | BT | Amgen's phase 3 trial of panitumumab shows positive results in colorectal cancer survival
|
4/3/2006 | BT | Merrill keeps Amgen at neutral
|
3/30/2006 | BT | Amgen, Abgenix complete BLA for FDA approval of panitumumab for colorectal cancer
|
3/30/2006 | BT | Amgen kept at neutral by Merrill
|
3/27/2006 | BT | Amgen gets FDA OK for extended dosing of Aranesp to treat chemotherapy-induced anemia
|
3/21/2006 | CV | Market Commentary: BioMarin comes in ahead of new issue; Casual Male seen as cheap; Vista delay could mean tech troubles
|
3/20/2006 | CV | Market Commentary: Kerzner buyout hurts hedge investors; BioMarin plans new deal; Time Warner Telecom offer seen as cheap
|
3/14/2006 | BT | Amgen reiterated at neutral by Credit Suisse
|
3/14/2006 | CV | Market Commentary: Fair Isaac plunges on fears of new rival product; Human Genome slides on mixed trial results
|
3/13/2006 | BT | Amgen says Aranesp may provide clinical benefits in heart failure patients
|
3/9/2006 | CV | Market Commentary: General Motors get boost from rumors of union deal; Transocean, Amgen stronger; MOL to launch deal
|
3/8/2006 | BTCV | Amgen files debt, stock shelf
|
3/3/2006 | CV | Market Commentary: Intel holds up on hedged basis despite stock slide; Citigroup says convertible arbitrage paid off in February
|
2/22/2006 | BT | Amgen reports investigational therapy Denosumab increases bone mineral density
|
2/22/2006 | CV | Market Commentary: MeriStar dives on buyout news; QLT gains despite wider losses; Amgen strong
|
2/21/2006 | BTCV | New Issue: Goldman Sachs prices $14.3 million 0.75% notes mandatorily exchangeable for Amgen
|
2/17/2006 | CV | Market Commentary: Citadel gains on rumors of put-seeking hedge funds; Amgen's new issues continue week's climb
|
2/16/2006 | BT | Amgen maintained at neutral by Merrill
|
2/16/2006 | CV | Market Commentary: Amgen convertibles active in trade; Halliburton gains; XM Satellite lower
|
2/15/2006 | BT | Market Commentary: Pfizer peddling ¥50 billion bonds; Amgen up out of chute; Adolor at bat; Ranbaxy taps convertibles market
|
2/15/2006 | CV | Market Commentary: New Amgen convertibles lift in active trade; Cephalon rises on guidance, Delta Air Lines weakens
|
2/14/2006 | BT | Market Commentary: Amgen rejigs deal, still a magnet to convertibles, stock players; Chelsea, YM taps PIPEs; Nektar breaks out
|
2/14/2006 | CV | Market Commentary: Amgen prices upsized $5 billion issue; Transocean takes a dive on flat outlook; Akela Capital calls it quits
|
2/14/2006 | BTCV | New Issue: Amgen's upsized $5 bln convertibles: 0.125%, up 11% for 5-year, 0.375%, up 10.5% for 7-year
|
2/13/2006 | CV | Market Commentary: Oil and gas plays Chesapeake, Nabors fall on lower oil prices; all eyes on Amgen, GM in week ahead
|
2/13/2006 | BTCV | Amgen $4 bln convertibles: 5-year talked at 0.125%-0.625%, 7-year at 0.375%-0.875%, both up 10-13%
|
2/13/2006 | BT | Amgen, Biovitrum expand license agreement for inhibitor of metabolic disorder enzyme
|
2/13/2006 | BT | Market Commentary: Amgen up after-hours as $4 billion convert emerges; Genentech off; Adolor down on deal; Alnylam up
|
2/13/2006 | BTCV | S&P rates Amgen convertibles A+
|
2/13/2006 | BTCV | Moody's rates Amgen convertibles A2
|
2/2/2006 | BT | Amgen to invest $1 billion in expanding manufacturing in Puerto Rico
|
2/1/2006 | BT | Merrill maintains Amgen at neutral
|
2/1/2006 | BT | Jefferies keeps Amgen at hold
|
1/27/2006 | BT | Amgen downgraded to neutral by Merrill
|
1/27/2006 | BT | Jefferies cuts Amgen to hold from buy
|
1/26/2006 | BT | Amgen, Genentech sign license agreements for antibody patents
|
1/26/2006 | BT | Amgen rating lowered to neutral by Merrill
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/25/2006 | BT | Amgen gets buy rating from Jefferies
|
1/25/2006 | BT | Market Commentary: Teva launches $2.75 billion bonds; NitroMed pockets $52.6 million; SGX Pharma sweetens IPO talk
|
1/24/2006 | BT | Amgen expands operations, invests $1 billion in facilities in Ireland
|
1/23/2006 | BT | Merrill reiterates Amgen at buy
|
1/12/2006 | CV | Market Commentary: Convertibles market turns mostly lower; biotechs, autos, oil services down, but Six Flags gains
|
1/11/2006 | BT | Market Commentary: PDL, OSI Pharma, Biogen dive; Altus IPO launches, Vertex eases; Novogen shelves Glycotex IPO
|
1/9/2006 | BT | Human Genome Sciences licenses gene to Amgen
|
1/9/2006 | BT | Market Commentary: Human Genome, Amgen higher on license pact; Alnylam soars on 2006 view; NPS, Oscient up big
|
1/6/2006 | BT | Market Commentary: Affymetrix lower, Millennium up on guidance; amid rotation into small caps Amgen, Genentech slide
|
1/3/2006 | BTCV | New Issue: Lehman prices $10.72 million notes linked to Amgen at 0.25%, up 10.75%
|
12/19/2005 | BTCV | Moody's affirms Amgen
|
12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
12/15/2005 | BT | S&P: Amgen unchanged
|
12/15/2005 | BT | Merrill maintains Amgen at buy
|
12/15/2005 | BT | Amgen maintained by Jefferies at buy
|
12/15/2005 | BT | Amgen maintained by Bear Stearns at peer perform
|
12/15/2005 | BT | Market Commentary: OSI Pharma on deck; Oxigene off on steep discount; BioCryst slips on PIPE; Somaxon sinks on debut
|
12/14/2005 | BT | Amgen to acquire Abgenix for $2.2 billion
|
12/14/2005 | BT | Market Commentary: BB Biotech deal on tap Friday; Amgen, Abgenix ink long-awaited merger; Oxigene seen on deck
|
12/13/2005 | BT | Amgen still buy, Jefferies says
|
12/12/2005 | BT | Amgen reports Arenesp cut need for transfusions in phase 3 trial for anemia
|
12/12/2005 | BT | Amgen reports interim phase 2 data shows Aranesp helps patients with myelodysplastic syndrome
|
12/12/2005 | BT | Amgen AMG 531 follow-up shows platelet increases for immune thrombocytopenic purpura
|
12/7/2005 | BT | Amgen announces $5 billion stock repurchase plan
|
12/7/2005 | BT | Galapagos, Amgen extend ion channel development collaboration
|
12/7/2005 | BT | Market Commentary: Voyager IPO at bat; Amgen off; ViroPharma jumps after deal; Dendreon slides; Rigel up sharply
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/21/2005 | CV | Market Commentary: GM mixed in light trade, Ford flat, Incyte gains on Pfizer pact, but SFBC falls
|
11/14/2005 | BT | Jefferies maintains Amgen at buy
|
11/10/2005 | BT | Merrill maintains Amgen at buy
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
11/9/2005 | BT | Amgen files suit against F. Hoffmann-LaRoche, alleging infringement of Epogen patents
|
11/8/2005 | BT | William Blair begins coverage of Amgen at outperform
|
11/7/2005 | BT | Market Commentary: Solid earnings fuel ViroPharma stock; Guidant sues Johnson & Johnson over proposed merger
|
11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
11/4/2005 | BT | Market Commentary: Introgen's stock lifts on Colgate-Palmolive alliance; Cytori, Olympus enter into joint venture
|
11/3/2005 | BT | Market Commentary: Abgenix, Amgen stocks take off on successful phase III study; Merck wins legal battle over Vioxx
|
11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
11/3/2005 | BT | Amgen, Abgenix panitumumab colorectal cancer study shows positive results
|
11/3/2005 | BT | Merrill maintains Amgen buy rating
|
11/2/2005 | BT | Bear Stearns maintains Amgen at peer perform
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
10/31/2005 | BT | Merrill Lynch reiterates Amgen at buy
|
10/20/2005 | CV | Market Commentary: Convertibles market reverses course after strong start; Cypress pulled down; Amgen, biotechs weaker
|
10/20/2005 | BT | Market Commentary: Predix IPO put on hold; Amgen spiral continues; Abgenix climbs; generics off despite Tamiflu talks
|
10/20/2005 | BT | Jefferies maintains Amgen at buy
|
10/19/2005 | BT | Market Commentary: Predix IPO on deck; Indevus up; Generex up; NeoPharm gains; Amgen plunges; Genta climbs
|
10/19/2005 | CV | Market Commentary: Ford, Amgen eyed before earnings; Continental lower, but AMR higher; Mercury Interactive gains
|
10/18/2005 | BT | Market Commentary: Amgen up; Abgenix, Cell Genesys lower; Chiron drops; Gilead sold on nice quarter; Genzyme seesaws
|
10/18/2005 | BT | Jefferies maintains Amgen at buy
|
10/18/2005 | BT | Merrill Lynch rates Amgen a buy
|
10/17/2005 | BT | Memory Pharmaceuticals announces more than $5 million license deal with Amgen
|
10/17/2005 | BT | Amgen, Genentech, Celgene among Merrill's picks for a rally, report says
|
10/3/2005 | BT | Amylin sales looking up as Biogen may face downside, Merrill report says
|
9/21/2005 | BT | Amgen price target raised by Merrill Lynch
|
9/20/2005 | CV | Market Commentary: US Airways, Toreador launch new deals, bringing calendar to five; Sepracor, Cephalon up
|
9/16/2005 | BT | Amgen reiterated by Bear Stearns at peer perform
|
9/15/2005 | CV | Market Commentary: Airlines under pressure; GM, Ford mostly lower; Cephalon higher, Amgen firm
|
9/14/2005 | BT | Amgen kept by Bear Stearns at peer perform
|
9/12/2005 | CV | Market Commentary: Northwest drops as other airline convertibles trade mixed; software names see better bids
|
9/9/2005 | BT | Amgen reiterated by Merrill Lynch at buy
|
9/8/2005 | CV | Market Commentary: Convertibles trade mixed, with Amgen, Nabors edging up, Cypress Semiconductor down
|
9/7/2005 | BT | Mature U.S. biotechs have stronger credit than industrials but weaker than Big Pharma, S&P says
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
8/1/2005 | CV | Market Commentary: CommScope jumps, but Isolagen tumbles amid slightly weaker convertibles market
|
7/29/2005 | BTCV | Moody's cuts Amgen to stable, rates convertible A2
|
7/25/2005 | BT | Amgen reiterated by Merrill at buy
|
7/22/2005 | BT | Market Commentary: Momenta gains at open, then goes south; Adams up against market; Durect convertibles up on buyback
|
7/21/2005 | CV | Market Commentary: Cheniere Energy to price $300 million deal; selling hits convertibles as Treasuries slump
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/20/2005 | CV | Market Commentary: Amgen rises in mixed convertibles trading as earnings reports roil GM, Kodak, boost Wyeth
|
7/20/2005 | BT | Amgen kept by Bear Stearns at peer perform
|
7/20/2005 | BT | Amgen estimates boosted by Thomas Weisel
|
7/20/2005 | BT | Amgen price target raised by Merrill Lynch
|
7/20/2005 | BT | Amgen price target upped by Jefferies
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
7/8/2005 | CV | Market Commentary: Biotechs, chips lead convertibles mostly higher; Charming Shoppes, Henry Schein trade higher
|
7/7/2005 | CV | Market Commentary: Biotechs up as convertibles find footing after early dip; airlines down; some oil and gas names extend gains
|
7/7/2005 | CV | Market Commentary: Biotechs up as convertibles find footing after early dip; airlines down; some oil and gas names extend gains
|
7/7/2005 | BT | Market Commentary: Accentia delays IPO on positive news; Salix takes off; Millipore gains; Sepracor off; Amgen soars
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
5/5/2005 | CV | Amgen receives tenders of 95% of 0% convertibles in exchange
|
5/4/2005 | CV | Amgen extends exchange for 0% convertibles
|
4/6/2005 | CV | Amgen starts exchange for 0% convertibles
|
3/2/2005 | CV | Amgen says $1.59 billion LYONs put back, leaving $2.36 billion outstanding
|
2/22/2005 | CV | Amgen offers cash payment to holders who do not exercise put
|
11/15/2004 | CV | Moody's rates Amgen notes A2
|
9/30/2004 | CV | Market Commentary: Ford, GM convertibles see little traffic ahead of Sept sales; Schering-Plough shoots up
|
7/22/2004 | CV | New Issue: Goldman prices $16.6 million notes exchangeable for Amgen to yield 1.5%, up 24.875%
|
7/21/2004 | CV | New Issue: Goldman prices $13 million notes exchangeable for Amgen to yield 1.5%, up 24.75%
|
7/15/2004 | CV | Market Commentary: Caesars eases back to levels before Harrah's deal; EDS off 1.75-2.25 points on cut to junk
|
6/17/2004 | CV | Market Commentary: Chiron goes to 101, Advanced Medical to 103.5; Kellwood to 101.5; Delta reverses, heads up
|
3/29/2004 | CV | S&P: Amgen unaffected
|
3/17/2004 | CV | Market Commentary: Cytyc goes to 104.375; XL prices at tight end of revised talk; Saks, Greater Bay, CommScope appear
|
12/17/2003 | CV | S&P: Amgen unaffected by share buyback
|
11/14/2003 | CV | Market Commentary: Valeant 3s end at 103.75 bid, 4s end at 104.75 bid; Amgen converts resist slide with stock
|
10/20/2003 | CV | Market Commentary: Hedgies buying Calpine notes; Amgen loses 1-2 points ahead of earnings; Nextel up on buybacks
|
9/29/2003 | CV | Market Commentary: Gap, Charming Shoppes show mixed views on retail results; Pharma Resources gains 2.25
|
7/11/2003 | CV | Lehman finds options market signaling several converts have high dividend risk
|
6/20/2003 | CV | Moody's confirms GM, outlook still negative
|
2/24/2003 | CV | Market Commentary: Very slow trading day, with players hanging in shadows
|
1/2/2003 | CV | Market Commentary: Market unexpectedly lively as new year opens strongly
|
11/25/2002 | CV | New Issue: Salomon sells $35 million 10% Targets linked to Amgen
|
11/14/2002 | CV | New Issue: Merrill Lynch prices $45.52 million 7% callable Strides payable with Amgen
|
8/28/2002 | CV | Market Commentary: Nortel drags down networkers; Semtech pressures chip group
|
7/18/2002 | CV | S&P says Baxter charge raises questions
|
7/15/2002 | CV | Market Commentary: Converts close higher despite wild swing in stock markets
|
6/13/2002 | CV | S&P revises Omnicom outlook to negative
|
5/22/2002 | CV | Market Commentary: Adelphia firms on buzz of Rigas deal; Berkshire surprises with overnighter
|
5/9/2002 | CV | Market Commentary: Adelphia gains on asset sales news; Household lower on put speculation
|
3/21/2002 | CV | Moody's puts DDi convertible on review for downgrade
|
2/22/2002 | CV | Moody's rates new Amgen convertible at A2
|
2/22/2002 | CV | Market Commentary: Convertibles mixed, flat on doubts, anxiety
|
2/22/2002 | CV | New Issue: Amgen $2.5 billion (proceeds) convertibles yield 1.125%, up 40%
|
2/21/2002 | CV | Amgen $2.5 billion (proceeds) convertibles talked at 1.0-1.25% yield, up 40-45%
|
2/21/2002 | CV | Moody's confirms Key Energy, rates add-on notes at Ba3
|
2/21/2002 | CV | Market Commentary: Convertibles retreat amid selling as stocks backslide
|
11/29/2001 | CV | New Issue: UBS prices $27 million 10.5% GOALS linked to Amgen
|
11/21/2001 | CV | Market Commentary: Convertible market dips slightly, ready for break to digest new issues
|